Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Upland, California Clinical Trials

A listing of Upland, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (38) clinical trials

A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE)

M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE)

Phase

0.0 miles

Learn More »

Safety and Efficacy of Filgotinib and GS-9876 in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

The primary objective of this study is to evaluate the efficacy of filgotinib and GS-9876 in females with moderately-to-severely active cutaneous lupus erythematosus (CLE).

Phase

0.84 miles

Learn More »

Efficacy and Safety of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU)

The purpose this study is to evaluate the efficacy, safety, and pharmacokinetics of GDC-0853 compared with placebo in participants with Chronic Spontaneous Urticaria (CSU) refractory to anti-histamines.

Phase

0.84 miles

Learn More »

A Clinical Trial of KT07 Capsule in the U.S.A

The purpose of this study is to investigate clinical efficacy of KT07 capsule in alleviation of fever and other symptoms including nasal congestion, sore throat, cough, aches and pains, fatigue, headache, chills or sweats in subjects with acute uncomplicated influenza.

Phase

1.3 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

The study consists of four phases: 4-week Screening Phase 24-week placebo-controlled phase Subjects will receive either 0.45 mg QD, 0.3 mg QD, 0.15 mg QD or placebo for the first 24 weeks of treatment. 28-week active treatment phase At Week 24, all subjects on placebo will be re-randomized to active ...

Phase

1.3 miles

Learn More »

Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)

The primary purpose of the study is to evaluate the efficacy of BIIB059 in reducing disease activity in participants with systemic lupus erythematosus (SLE) with active cutaneous manifestations and joint involvement (Part A), and in participants with active cutaneous lupus erythematosus (CLE) (Subacute cutaneous lupus erythematosus (SCLE) or chronic CLE, ...

Phase

1.3 miles

Learn More »

A Study to Evaluate the Efficacy Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder

The purpose of this 2 month phase 2b study is to investigate the dose response of 3 doses of JNJ-42847922 (Seltorexant) (5,10 and 20 mg) compared to placebo and zolpidem on sleep onset and maintenance and to further document safety and tolerability of JNJ-42847922 (Seltorexant) upon multiple (14 days) dose ...

Phase

1.3 miles

Learn More »

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate Frequent Urination Associated With Wetting Episodes (VEL-2001)

This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of solabegron modified release low dose or high dose tablets, compared to matched placebo, administered once daily for 12 weeks to adult female subjects with overactive bladder symptoms (frequency, urgency, and ...

Phase

1.3 miles

Learn More »

A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression

The purpose of this study is to evaluate the efficacy of JNJ-67953964 compared to placebo when administered as adjunctive treatment in participants with Major Depressive Disorder (MDD) partially responsive to selective serotonin reuptake inhibitor/ serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) treatment in terms of reduction of symptoms of depression, as assessed by ...

Phase

1.3 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder

MIN-117C03 is a 6-week, 3-arm, randomized, double-blind, placebo-controlled study to investigate the safety and efficacy of MIN-117 in male and female patients with Major Depressive Disorder, aged 18 to 65 years. Approximately 324 patients will be randomly assigned to 1 of 3 treatment arms, including placebo, 5.0 mg MIN-117, or ...

Phase

1.3 miles

Learn More »